Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of “Moderate Buy” by Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $17.39.

A number of equities analysts recently weighed in on ROIV shares. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. Bank of America lifted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Piper Sandler upped their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th.

Insider Buying and Selling

In other Roivant Sciences news, Director Keith S. Manchester sold 368,052 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of $11.62, for a total transaction of $4,276,764.24. Following the completion of the transaction, the director now owns 1,412,126 shares of the company’s stock, valued at approximately $16,408,904.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Financial Lp Qvt sold 876,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the transaction, the director now owns 22,179,358 shares in the company, valued at $262,160,011.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Keith S. Manchester sold 368,052 shares of the stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $11.62, for a total transaction of $4,276,764.24. Following the completion of the transaction, the director now directly owns 1,412,126 shares of the company’s stock, valued at $16,408,904.12. The disclosure for this sale can be found here. Insiders have sold 3,477,309 shares of company stock valued at $40,986,184 over the last ninety days. 4.60% of the stock is owned by insiders.

Institutional Trading of Roivant Sciences

Several large investors have recently bought and sold shares of the company. Rubric Capital Management LP boosted its position in shares of Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares in the last quarter. Vanguard Group Inc. lifted its position in Roivant Sciences by 14.6% during the first quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after buying an additional 1,030,681 shares during the period. DME Capital Management LP boosted its holdings in shares of Roivant Sciences by 14.8% during the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock valued at $50,852,000 after buying an additional 620,470 shares in the last quarter. Norges Bank purchased a new stake in shares of Roivant Sciences in the 4th quarter worth about $41,506,000. Finally, BlackBarn Capital Partners LP increased its stake in shares of Roivant Sciences by 63.1% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock worth $32,767,000 after acquiring an additional 1,199,406 shares in the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Trading Down 0.8 %

Shares of Roivant Sciences stock opened at $11.48 on Wednesday. The company has a 50 day simple moving average of $11.50 and a two-hundred day simple moving average of $11.09. The firm has a market cap of $8.48 billion, a PE ratio of 2.27 and a beta of 1.25. Roivant Sciences has a 1 year low of $8.24 and a 1 year high of $13.24. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same period in the previous year, the business earned ($0.38) earnings per share. The firm’s quarterly revenue was up 155.1% compared to the same quarter last year. Analysts expect that Roivant Sciences will post -1.14 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.